COVID-19 therapeutics update: Sotrovimab no longer included in allocation, Bebtelovimab is alternate mAb, EVUSHELD eligibility

March 31, 2022

The spectrum of medical therapies to treat COVID-19 continues to evolve and address SARS-CoV-2 variants. Sotrovimab no longer included in the Washington State allocation/distribution. Bebtelovimab is the alternate mAb for treatment and is readily available for allocation from the Washington State Department of Health. The DOH also no longer recommends the use of a tiered system to determine eligibility for EVUSHELD. For questions related to therapeutics, please reach out to the Washington State Department of Health Medical Countermeasure Team at Please review the resources below for additional information:


Contact Us

Washington State Hospital Association
999 Third Avenue
Suite 1400
Seattle, WA 98104

Map / Directions

206.281.7211 phone
206.283.6122 fax

Staff List